Top Story
- Medical Affairs
Bristol Myers Squibb (BMS) has initiated a significant workforce reduction at the headquarters of the recently acquired Mirati Therapeutics in San Diego, California, letting go of 252 employees. This move follows the closure of their merger in late January, where BMS purchased the cancer-focused biotech for [...]
Latest Stories
- Patient Outcomes & Engagement
- Patient Outcomes & Engagement
- Patient Outcomes & Engagement
Featured Webinars
Beyond Accelerated Approvals: External Control Arms
Wednesday, April 10, 2024
Sponsor: Cardinal Health
Delphi Panels: What Are They Good For?
Tuesday, March 12, 2024
Sponsor: Partnership for Health Analytic Research (PHAR)
Patient Voices Matter: Transforming Industry-Sponsored Real-World Evidence with Patient-Centric Approaches
Thursday, February 29, 2024
Sponsor: Carelon Research
Integrated Evidence Generation Planning: Driving Successful Reimbursement and Life Cycle Management
Tuesday, February 27, 2024
Sponsor: OPEN Health
Handpicked Promotions & Highlights
Latest in Catalyst News powered by BioPharmCatalyst
Gamida Cell Ltd. AVTE date announcement
Aerovate Therapeutics plans to announce top-line results for their Phase 2/3 trial of AV-101 - (IMPAHCT) on June 30, 2024. As of now, the drug has a 29.6% chance of moving on.
Aerovate Therapeutics rocketed [...]
Read MoreLongeveron AVIR date announcement
Now that the Phase 3 trial of Bemnifosbuvir (AT-527) - (SUNRISE-3) is completed, Atea Pharmaceuticals will announce their top-line results on March 31, 2024. The community is currently bullish on the prospects of progression, as [...]
Read MoreSearch HealthEconomics.com
Throw in a keyword, research topic, disease model or technology of interest